tradingkey.logo

SparingVision Successfully Completes Prodygy Trial Patient Dosing With Spvn06, Its Novel Neuroprotective Gene Therapy

ReutersFeb 9, 2026 12:07 PM

-

  • SPARINGVISION SUCCESSFULLY COMPLETES PRODYGY TRIAL PATIENT DOSING WITH SPVN06, ITS NOVEL NEUROPROTECTIVE GENE THERAPY

  • SPARINGVISION: INITIAL DATA READOUT FOR NOVEL GENE-AGNOSTIC THERAPY EXPECTED IN 2027

  • SPARINGVISION: ALL PATIENTS DOSED WITH SPVN06 IN PHASE I/II TRIAL CONTINUE TO DEMONSTRATE A FAVORABLE SAFETY PROFILE

Further company coverage: [ ]

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI